SSA
OACC

Schonfeld Strategic Advisors’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

Schonfeld Strategic Advisors’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.17M Sell
110,107
-5,067
-4% -$53.9K 0.01% 1020
2025
Q4 		$1.22M Sell
115,174
-9,826
-8% -$104K 0.01% 1049
2025
Q3 		$1.31M Sell
125,000
-430,000
-77% -$4.49M 0.01% 1251
2025
Q2 		$5.8M Buy
555,000
+195,800
+55% +$2.03M 0.04% 524
2025
Q1 		$3.67M Buy
+359,200
New +$3.61M 0.02% 647

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $386M AUM 45.42% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.27B AUM 25.46% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BGIM
Boussard & Gavaudan Investment Management London, United Kingdom $1.06B AUM 4.58% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Schonfeld Strategic Advisors's OACC Position: Q1 2026 in Review

Schonfeld Strategic Advisors reduced its Oaktree Acquisition Corp III Life Sciences (OACC) stake by 4.4% in Q1 2026, selling an estimated $53.9K and leaving 110,107 shares worth $1.17M. The position accounts for 0.01% of the portfolio, ranked #1020.

Schonfeld Strategic Advisors first reported a position in OACC in Q1 2025 and has held it in 5 quarters since. The position peaked at $5.8M in Q2 2025. 51 funds tracked by Wall St. Rank hold OACC as of Q1 2026.

  • Schonfeld Strategic Advisors held 110,107 shares of Oaktree Acquisition Corp III Life Sciences worth $1.17M as of Q1 2026.
  • Schonfeld Strategic Advisors sold 5,067 Oaktree Acquisition Corp III Life Sciences shares in Q1 2026, an estimated $53.9K.
  • Oaktree Acquisition Corp III Life Sciences made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1020 holding.
  • Schonfeld Strategic Advisors first reported a position in Oaktree Acquisition Corp III Life Sciences in Q1 2025 and has held it in 5 quarters since.
  • Schonfeld Strategic Advisors's Oaktree Acquisition Corp III Life Sciences position peaked at $5.8M in Q2 2025.
  • 51 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.